Shares of Inflarx NV (NASDAQ:IFRX) have earned a consensus broker rating score of 1.00 (Strong Buy) from the four brokers that cover the company, Zacks Investment Research reports. Four analysts have rated the stock with a strong buy rating.
Brokerages have set a 12-month consensus price target of $39.01 for the company and are predicting that the company will post ($0.34) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Inflarx an industry rank of 183 out of 265 based on the ratings given to related companies.
A number of research firms have recently weighed in on IFRX. Zacks Investment Research cut Inflarx from a “hold” rating to a “sell” rating in a research report on Saturday. B. Riley started coverage on Inflarx in a report on Thursday, February 8th. They issued a “buy” rating and a $40.00 price target on the stock. Finally, Leerink Swann boosted their price target on Inflarx from $31.00 to $36.00 and gave the stock an “outperform” rating in a report on Monday, April 2nd.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Redmile Group LLC purchased a new position in Inflarx in the 4th quarter worth approximately $17,960,000. Millennium Management LLC bought a new stake in Inflarx in the 4th quarter worth approximately $1,063,000. Deutsche Bank AG bought a new stake in Inflarx in the 4th quarter worth approximately $733,000. Amundi Pioneer Asset Management Inc. bought a new stake in Inflarx in the 4th quarter worth approximately $126,000. Finally, BlackRock Inc. bought a new stake in Inflarx in the 4th quarter worth approximately $31,129,000. 43.33% of the stock is currently owned by institutional investors.
IFRX stock opened at $27.40 on Friday. Inflarx has a twelve month low of $14.47 and a twelve month high of $34.86.
ILLEGAL ACTIVITY WARNING: This piece of content was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/07/zacks-inflarx-nv-ifrx-given-consensus-recommendation-of-strong-buy-by-brokerages.html.
Inflarx Company Profile
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company’s primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases.
Get a free copy of the Zacks research report on Inflarx (IFRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inflarx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inflarx and related companies with MarketBeat.com's FREE daily email newsletter.